Global Cardiopulmonary Exercise Testing Market Size, Segmentation, Trends and Growth Analysis Forecast by 2031

Cardiopulmonary Exercise Testing Market Overview and Analysis

The Global Body Cardiopulmonary Exercise Testing Market is currently valued at USD 5.8 billion in 2022 and is expected to register a CAGR of 7.5% over the forecast period 2022-2031.

The Cardiopulmonary Exercise Test (CPET) is a non-invasive method used to assess the performance of the heart and lungs at rest and during exercise. With the use of outstanding technology, the patient’s breathing pattern, the amount of oxygen the body is using, and the amount of carbon dioxide it is producing will indicate the level of exercise and one’s threshold when exerting effort during physical activities, such as in sports.

While the patient undergoes the CPET, the following equipment will be used to monitor the body’s activity; 1) face mask (for oxygen expenditure and carbon dioxide production); 2) electrocardiogram or EKG (for heart rate and rhythm monitoring); 3) blood pressure cuff (for blood pressure monitoring) and; 4) pulse oximeter (for measurement of blood cells covered with oxygen). A highly skilled and trained doctor will record, test, and assess the patient’s body’s maximum limits depending on his performance during the test.

Segmentation :

The Cardiopulmonary Exercise Testing Systems Market is Segmented

By Product Type :

• Exercise Testing Systems
• Stress ECG
• Stress Blood Pressure Monitors
• Other

End User :

• Hospitals & Specialty Clinics
• Ambulatory Surgical Centers
• Other

Geography :

• North America
• Europe
• Asia-Pacific
• Middle East
• Africa
• South America

The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

Driver : 

Cardiopulmonary Exercise Testing Market Rise in Global Healthcare Expenditure

For instance, The Survey conducted by the Government of India in 2023, reported the increase in the share of expenditure on health in total expenditure on social services, which has risen from 21% in FY19 to 26 % in FY23 (BE), underscores the rising importance of public healthcare and social security in ensuring universal health coverage. Furthermore, Rising R&D studies proving the efficiency of cardiopulmonary stress tests in detecting cardiopulmonary conditions may further boost the market's growth. For instance, the Annual Report published by GE Healthcare in 2023, reported

Revenue for cardiopulmonary diagnostic and imaging devices increased by USD 1.3 billion (7%) in 2022, organically mainly due to strong growth in the U.S. and Europe, the Middle East, and Africa, partially offset by China. Thus, such instances are constantly propelling the studied market growth.

Rise in Global Prevalence of Cardiopulmonary Disorder

The problems of cardiovascular diseases have also increased due to the rise in work pressure and stress among the people belonging to the younger generation. The people belonging to the geriatric age group already present a number of cardiovascular disorders which helps to boost the market of cardiovascular drugs tremendously. Even minor alterations in the rhythm or rate of the cardiovascular system help the cardiovascular drug market to grow considerably. Not only the elderly people but also the younger generation present a number of cardiovascular complaints as a result of their lifestyle practices. With the prevalence of cardiac arrest among people, the market for cardiovascular drugs has been boosted tremendously.

Restraints High Cost of Cardiovascular Exercise Testing Devices

Cardiovascular exercise testing devices are quite expensive and thus this may limit their usage for people living in developing countries, thereby slowing down the growth of the studied market. For instance, the update published by the University of Surrey in 2021, reported that the Cardiopulmonary exercise test (CPET) cost varies around EUR 120. Thus, such instances report the high cost of testing may slow down the market growth.

Covid -19 Impact on Cardiopulmonary Exercise Testing Market

The COVID-19 pandemic largely impacted healthcare systems worldwide and so has had a significant impact on the global cardiopulmonary exercise testing market. For instance, a study published by an article by NCBI in January 2021 reported that circulatory impairment, abnormal ventilatory pattern, and myalgia encephalomyelitis/chronic fatigue syndrome were some of the most common disorders reported in patients with post-acute sequelae of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection (PASC), as a result, there was an increasing need for cardiopulmonary stress testing equipment to assess cardiac stress. Such instances boosted the demand for the cardiopulmonary exercise testing market during COVID-19. In the current scenario, it is estimated that due to a decrease in COVID-19 cases, the demand for cardiopulmonary devices may stabilize compared to the beginning of the pandemic. However, due to various implementations of cardiopulmonary exercise testing across various healthcare sections, the market is expected to witness significant changes over the forecast period.

Segmental Analysis:

Stress ECG Segment is Expected to Witness Significant Growth over the Forecast Period

A cardiac stress test is a cardiological test that measures the heart's ability to respond to external stress in a controlled clinical environment. The stress response is induced by exercise, intravenous pharmacological stimulation, or in some cases, a combination of both. A stress test or exercise stress test gives doctors a way to check the way the heart functions while one is physically active. This kind of test can show whether or not there are any problems with the way blood flows in the heart, which could indicate heart disease or other heart problems. Thus, the segment is expected to witness significant growth over the forecast period.

Hospitals & Specialty Clinics segment is expected to witness significant growth over the Forecast Period

The segment is expected to witness significant growth owing to easy availability and access to devices in these centers. Also, patients can easily find these canters nearby, so the segment is expected to witness significant growth over the forecast period.

North America is Expected to Hold a Major Share of the Market

North America is expected to dominate the cardiopulmonary stress testing (CPST) systems market throughout the forecast period. The United States is expected to register significant growth during the forecast period. The rising prevalence of cardiovascular and pulmonary disorders such as arrhythmia, heart failures, ischemic heart disease, dyspnea, and heart valve imbalance in the United States, generating higher demand for CPST systems.

The statistics published by the National Association for Chronic Disease Directors in April 2022, reported that nearly 60% of adult Americans have at least one chronic disease in the year 2021, and and cardiovascular disease has affected more than two-thirds of all deaths in the region. The source also reported that cardiovascular disease is responsible for one in three deaths in 859,000 people in the United States. Thus, such instances show a high number of cardiovascular diseases increasing the demand for cardiovascular exercise testing devices in the region.

Cardiopulmonary Exercise Testing Market Competitive Landscape

The cardiopulmonary exercise testing systems market is moderately competitive and consists of several major players. In terms of market revenue, a few prominent players currently dominating the market are vigorously making acquisitions with other companies to consolidate their market positions across the world. Some of the companies currently dominating the market are :

Key Players :

• Koninklijke Philips NV
• Hillrom Services Inc.
• General Electric Company
• MGC Diagnostics Corporation
• OSI Systems Inc.

Recent Development

1) In February 2022, InBody launched the BP 170 automatic blood pressure monitor, which provides individuals with the option to self-record and track key health metrics at home.

2) In January 2022: Aktiia, reported the launch of a 24/7 Blood Pressure Monitor to the United States, delivering the next generation of clinical wearables specifically designed to meet the needs of both patients and physicians. Consumer wearables have struggled to gain acceptance and trust in the healthcare community. Eighty-one per cent of physicians would not decide on a patient's treatment or care based on data from a consumer wearable. By comparison, physicians across Europe are already utilizing Aktiia to personalize their patients' care. 

Frequently Asked Questions (FAQ) :

Q1. What is the market size of the Cardiopulmonary Exercise Testing Market ?

Q2. Which factor is Limiting the growth of Cardiopulmonary Exercise Testing Market ?

Q3. Which Region is expected to hold the highest Market share?

Q4. What segments are covered in the Cardiopulmonary Exercise Testing Market Report?